Comparative Pharmacology
Head-to-head clinical analysis: BENDEKA versus CYCLOPHOSPHAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENDEKA versus CYCLOPHOSPHAMIDE.
BENDEKA vs CYCLOPHOSPHAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bendamustine is a bifunctional mechlorethamine derivative with alkylating and antimetabolite properties. It forms cross-links between DNA strands, leading to DNA synthesis inhibition and apoptosis. The exact mechanism also involves activation of p53-dependent and p53-independent stress pathways, and inhibition of mitotic checkpoints.
Cyclophosphamide is an alkylating agent that crosslinks DNA, leading to cell cycle nonspecific cytotoxicity. It requires hepatic metabolism by cytochrome P450 (CYP2B6, CYP3A4, CYP2C9) to form active metabolites, phosphoramide mustard and acrolein, which alkylate DNA and inhibit protein synthesis.
120 mg/m2 intravenously infused over 10 minutes on Days 1 and 2 of a 28-day cycle, up to 6 cycles.
400-600 mg/m2 IV every 2-4 weeks; or 50-100 mg/m2 orally daily for 7-14 days; or 1-2 g/m2 IV as a single dose every 3-4 weeks.
None Documented
None Documented
Clinical Note
moderateCyclophosphamide + Verteporfin
"Cyclophosphamide may increase the cardiotoxic activities of Verteporfin."
Clinical Note
moderateCyclophosphamide + Digoxin
"Cyclophosphamide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCyclophosphamide + Digitoxin
"Cyclophosphamide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCyclophosphamide + Deslanoside
Terminal elimination half-life is approximately 40 minutes for bendamustine; active metabolite (gamma-hydroxybendamustine) has half-life of about 3 hours. Clinical context: short half-life allows for rapid clearance, but requires frequent dosing.
Terminal elimination half-life: 4-8 hours in adults with normal renal function; prolonged in renal impairment (up to 15 hours) and in children.
Primarily renal excretion (approximately 50% as unchanged drug and metabolites); biliary/fecal elimination is minor (<5%).
Renal: approximately 30-60% of dose excreted unchanged in urine; biliary/fecal excretion is minimal (<5%).
Category C
Category D/X
Alkylating Agent
Alkylating Agent
"Cyclophosphamide may decrease the cardiotoxic activities of Deslanoside."